EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Implications of Trial Eligibility in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Anthony E Peters, Robert M Clare, Karen Chiswell, Josephine Harrington, Anita Kelsey, Adrian Hernandez, Gary Michael Felker, Robert J Mentz, Adam D DeVore

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14777 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Anthony E Peters und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Duke University School of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Clinical trials in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to challenges with efficient enrolment and questions regarding the generalizability of trial findings. Methods and results Patients with HFmrEF/HFpEF from a large US healthcare system were identified through a computable phenotype applied in linked imaging and electronic health record databases. We evaluated shared eligibility criteria from five recent/ongoing HFmrEF/HFpEF trials (PARAGON-HF, EMPEROR-Preserved, DELIVER, FINE-ARTS, and SPIRRIT-HFpEF) and compared clinical and echocardiographic features as well as outcomes between trial-eligible and trial-ineligible patients. Among 5552 patients with HFpEF/HFmrEF, 792 (14%) were eligible for trial consideration, having met all criteria assessed. Causes of ineligibility included lack of recent loop diuretics (37%), significant pulmonary disease (24%), reduced estimated glomerular filtration rate (17%), recent stroke/transient ischaemic attack (13%), or low natriuretic peptides (12%); 53% of ineligible patients had >1 reason for exclusion. Compared with eligible patients, ineligible patients were younger (age 71 vs. 75 years, P < 0.001) with higher rates of coronary artery disease (66% vs. 59%, P < 0.001) and peripheral vascular disease (40% vs. 33%, P < 0.001), but less mitral regurgitation, lower E/e′ ratio, and smaller left atrial sizes. Both eligible and ineligible patients demonstrated high rates of structural heart disease consistent with HFpEF [elevated left atrial size or left ventricular (LV) hypertrophy/increased LV mass], although this was slightly higher among eligible patients (95% vs. 92%, P = 0.001). The two cohorts demonstrated similar LV global longitudinal strain along with a similar prevalence of atrial fibrillation/flutter, hypertension, and obesity. Ineligible patients had similar all-cause mortality (33% vs. 33% at 3 years) to those eligible but lower rates of heart failure hospitalization (20% vs. 28% at 3 years, P < 0.001).

Conclusions

Among patients with HFmrEF/HFpEF from a large health system, approximately one in seven were eligible for major trials based on key criteria applied through a clinical computable phenotype. These findings highlight the large proportion of patients with HFmrEF/HFpEF ineligible for contemporary trials for whom the generalizability of trial findings may be questioned and further investigation would be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeHumansMaleFemaleAgedPatient SelectionClinical Trials as TopicEchocardiographyEligibility DeterminationMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

Clinical trialsEchocardiographyHeart failure with preserved ejection fraction

Autor:innen und Institutionen

  • Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
  • Duke Clinical Research Institute, Durham, NC, USA.

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • Division of Intramural Research

Zitieren

APA

Peters, A. E., Clare, R. M., Chiswell, K., Harrington, J., Kelsey, A., Hernandez, A., Felker, G. M., Mentz, R. J., & DeVore, A. D. (2024). Implications of Trial Eligibility in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction. ESC Heart Failure. https://doi.org/10.1002/ehf2.14777

Vancouver

Peters AE, Clare RM, Chiswell K, Harrington J, Kelsey A, Hernandez A, et al. Implications of Trial Eligibility in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction. ESC Heart Failure. 2024. doi:10.1002/ehf2.14777

BibTeX
@article{Peters2024,
  author = {Peters, Anthony E and Clare, Robert M and Chiswell, Karen and Harrington, Josephine and Kelsey, Anita and Hernandez, Adrian and Felker, Gary Michael and Mentz, Robert J and DeVore, Adam D},
  title = {Implications of Trial Eligibility in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14777}
}
Kostenlos starten →